Biologic therapies for asthma in underserved populations
- PMID: 35964595
- PMCID: PMC10032547
- DOI: 10.1016/S0140-6736(22)01383-6
Biologic therapies for asthma in underserved populations
Conflict of interest statement
STW reports royalty payments from UpToDate for advice on the epidemiology of asthma and chronic obstructive pulmonary disease and is an unpaid board member of Histolix, a digital pathology company. RSK declares no competing interests.
Comment on
-
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet. 2022 Aug 13;400(10351):502-511. doi: 10.1016/S0140-6736(22)01198-9. Lancet. 2022. PMID: 35964610 Free PMC article. Clinical Trial.
References
-
- Gonzalez Burchard E, Borrell LN. Need for racial and ethnic diversity in asthma precision medicine. N EnglJ Med 2021; 385: 2297–98. - PubMed